ProfileGDS5678 / 1416355_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 55% 55% 54% 66% 53% 58% 55% 54% 55% 56% 53% 54% 53% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3889154
GSM967853U87-EV human glioblastoma xenograft - Control 23.3740155
GSM967854U87-EV human glioblastoma xenograft - Control 33.3803555
GSM967855U87-EV human glioblastoma xenograft - Control 43.2904154
GSM967856U87-EV human glioblastoma xenograft - Control 53.9230466
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.4000253
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.5863658
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3554955
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3062754
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3677155
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3968556
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2809953
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3608854
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.2961953